Talk To Our Team

Welcoming Will Dull

as BiotechExec’s Chief Operating Officer & Senior Client Advisor Dec ‘21

Untitled design (6)

An expert in executive leadership and operational management, with over 30 years of senior level experience and a Bachelor of Science degree, William (Bill) Dull is an exceptional asset to BiotechExec’s board; joining us as our Chief Operating Officer (COO). Bill is also an investor and serves as a Board Advisor to several companies.

Specialising in MedTech, Pharma and Biotech – Bill is an accomplished entrepreneur, manager and investor. He has built and led high-performing integrated teams; ranging from early-stage businesses in various industries, including (but not limited to) finance and manufacturing program management. Bill subsequently obtains a proven track record of dozens of successful product launches and business development transactions, and in addition to serving as partner and COO at BiotechExec, Bill is a member of our growing IGNITE Network and Senior Executive Advisory Team (SEAT). His multiple years experience leading Business Development/Corporate Strategy and negotiating profitable strategic partnerships, ranging from products, service and distribution/licensing agreements, intellectual property and manufacturing contracts add to his sterling reputation.

Bill enjoys leading fast-paced, high growth, scalable businesses with innovative and disruptive technologies that are patient centric. Being results driven, with an analytical mindset and a collaborative, inclusive management style makes Bill a perfect fit for BiotechExec.

Bill’s latest BiotchExec assignment was as a CEO of Innomed One, which is developing and commercializing novel medical devices for the infertility space. Prior to InnoMed, Bill was a founding member and Chief Commercial Officer at Renovia, a privately held MedTech company in women’s health.

Together with his fellow SEAT members, Bill will work with BiotechExec’s clients to define the scope of work that will bring the greatest benefit to their organization (like above). Our Senior Advisors will engage the members of our global network best equipped to deliver this scope and build commercial success to life science companies – to benefit their shareholders and customers, for the future of global healthcare.